Navigation Links
OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
Date:11/6/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 6, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the completion of patient enrollment in the primary registration Phase 3 study, known as SYNERGY, evaluating custirsen in patients with advanced prostate cancer.

The SYNERGY study is designed to evaluate a survival benefit for custirsen, when added to first-line chemotherapy, in men with metastatic castrate-resistant prostate cancer (mCRPC). The SYNERGY study is the first of two, ongoing, pivotal Phase 3 studies evaluating a potential survival benefit for custirsen treatment in prostate cancer. 

Over 1000 men have been enrolled to the SYNERGY study, at 142 sites primarily in North America and Europe. The survival primary endpoint data are event-driven and results are expected by the end of 2013.

"Completing enrollment of SYNERGY is an exciting and important milestone for the custirsen development program and for our company," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "We are one step closer to our goal of truly understanding the clinical benefit of custirsen in a large, randomized Phase 3 study, and to bringing forward a new treatment that could potentially extend the lives of men with prostate cancer."

The SYNERGY trial was initiated based on results of the OncoGenex Phase 2 trial in patients with metastatic CRPC receiving custirsen in combination with first-line docetaxel chemotherapy. These patients experienced a 6.9 month improvement in overall survival in comparison with those patients who received docetaxel alone.

Custirsen has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel. The FDA has also agreed on the design of the SYNERGY trial through the special protocol assessment (SPA) p
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AMRI Announces Third Quarter 2012 Results
2. Egenix, Inc. Announces New Director
3. BioRestorative Therapies Announces Stock Trading On OTC Bulletin Board
4. WebMD Announces Third Quarter Financial Results
5. Life Technologies Announces Third Quarter 2012 Results
6. HealthTech Capital Announces Awards for the HealthTech Conference 2012 - Building a Business in the New HealthTech Ecosystem
7. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
8. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
9. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
10. Synthetic Biologics Announces $10.8 Million Financing
11. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Los Angeles, CA (PRWEB) February 26, 2015 ... organizing an online demonstration to support life extension technologies ... to 8pm UTC, Universal Coordinated Time, on March 21st ... around the world. , Eric Schulke, Founder of ... we must act with urgency. The Movement for Indefinite ...
(Date:2/26/2015)... BioEnterprise today announced that Northeast Ohio ... in growth funding during the past 13 years.  Funding ... – including the Ohio Third Frontier - and federal ... raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
(Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015 ... Gold Partner status in Oracle PartnerNetwork. In attaining Gold ... its commitment to establish Oracle-related knowledge in delivering Ceres, ... challenges of joint customers. Originally developed for ... to rapidly zoom in and out of massive amounts ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4RURO Releases FreezerPro® version 6.2 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... and tumor specific data to,enhance the value of ... private financing. Under the terms of the private ... Company,s,common stock at $1.75 per share. There were ...
... Science,Corporation (Nasdaq: CSCX ), a global leader ... announced today,that it will release its first quarter ... the market close. The Company has scheduled a,conference ... Eastern Time to,discuss the financial results for the ...
... treating individuals with cancer would find a noninvasive method to ... because low levels of oxygen in a tumor have been ... this and to image the surrounding organs and tissues at ... tumors in mice by Murali Krishna and colleagues, at the ...
Cached Biology Technology:Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 2Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 3Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call 2
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:1/22/2015)... 22, 2015 Infinisource has launched its new NXG series ... The G2 sets a higher standard for collecting attendance and ... solution. With plug-and-play installation, touch screen interface and seamless connection ... robust time collection solution for the small to mid-size employer. ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... fishing ranges despite doing nothing to defend their territory ... team of researchers led by the University of Leeds ... which can fly hundreds of kilometres on a single ... from neighbouring colonies. The findings, published in the ...
... DUBLIN , June 6, 2013 ... addition of the "DNA Microarray 2013: A Focus ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,DNA Microarray 2013 ... DNA Microarray, involving the participation of 201 buyers and ...
... their enemies in order to kill them. They can,t be ... opponents. But indifference to the enemy, rather than loathing, may ... path back to healthy civilian lives, researchers at Case Western ... work showing how the brain operates when people objectifythat is, ...
Cached Biology News:Gannets don't eat off each other's plates 2Gannets don't eat off each other's plates 3DNA Microarray 2013 Market Report: A Focus on Sales Growth 2A way of thinking may enable battle but prevent war crimes 2A way of thinking may enable battle but prevent war crimes 3A way of thinking may enable battle but prevent war crimes 4A way of thinking may enable battle but prevent war crimes 5A way of thinking may enable battle but prevent war crimes 6
... targets including proteins and to their modification ... antigens. A&Gs service is divided into ... 40 days (duration may vary slightly dependent ... I: Immunization, test bleed and fusion; $2,500 ...
... Clone/PAD: ZMD.368. Immunogen: Synthetic peptide ... the human WNT2B/WNT13 protein. Specificity: ... mouse and rat WNT2B/WNT13 proteins. Recognizes ... Reactivity: Mouse Human Rat (positive ...
... Immunogen: Synthetic peptide derived from ... protein (chromosome 17 open reading frame 37 ... for the C35 protein. On Western blots ... kDa band. Reactivity: Human (positive control: ...
...
Biology Products: